SCHEMBL15106928

SCHEMBL15106928

C=CCc1c(F)cccc1-c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
RAB9A P51151 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.35
DPP4 P27487 2/20 0.35
RXRA P19793 1/20 0.34
PDCD1 Q15116 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
PKM P14618 1/20 0.34
NFKB1 P19838 1/20 0.34
MAPK1 P28482 1/20 0.34
NFKB2 Q00653 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9221316 0.82 TAAR1 (0.39) GABRA1GABRB2ALDH1A1KDM4ESMN1; SMN2
SCHEMBL31709207 0.81 LMNA (0.39) ALDH1A1KDM4ESMN1; SMN2RAB9ALMNA
SCHEMBL2362467 0.81 GABRA1 (0.52) GABRA1GABRB2ADRB2ADRB1ALDH1A1
SCHEMBL170430 0.80 ALDH1A1 (0.50) GABRA1GABRB2ADRB2ADRB1ALDH1A1
SCHEMBL4987129 0.80 ALDH1A1 (0.50) GABRA1GABRB2ADRB2ADRB1ALDH1A1
SCHEMBL5889004 0.80 GABRA1 (0.38) GABRA1GABRB2ADRB2ADRB1ALDH1A1
SCHEMBL6546847 0.80 PDCD1 (0.41) GABRA1GABRB2ADRB2ADRB1ALDH1A1
SCHEMBL15106903 0.80 CYP2A6 (0.50) GABRA1GABRB2ADRB2ADRB1ALDH1A1
SCHEMBL15106837 0.80 MAPK1 (0.50) GABRA1GABRB2ADRB2ADRB1ALDH1A1
Bromide SCHEMBL27823869 0.79 GABRA1 (0.49) GABRA1GABRB2ADRB2ADRB1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309188-B2 Method for allylating and vinylating aryl, heteroaryl, alkyl, and alkene halogenides using transition metal catalysis Saitigo GmbH (DE) 2016-04-12 US disclosed
US-20130184485-A1 Method for Allylating and Vinylating Aryl, Heteroaryl, Alkyl, and Alkene Halogenides Using Transition Metal Catalysis SALTIGO GMBH (DE) 2013-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130184485-A1 Method for Allylating and Vinylating Aryl, Heteroaryl, Alkyl, and Alkene Halogenides Using Transition Metal Catalysis VRK2, VRK1, GRK1 GABRA1 2728/4885GABRB2 3419/4885ADRB2 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.